REV3L

Across TCGA pan-cancer cohorts, REV3L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated REV3L data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher REV3L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated REV3L expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

HNSC, GBM, and LUAD are the cancer types where REV3L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.296	0.791	.021	10	view →
GBM	DFS	Quartile	All	0.596	0.242	.007	9	view →
LUAD	DFS	Tertile	III,IV	0.251	0.866	.024	8	view →
PDAC	DFS	Median	II,III,IV	0.988	0.375	.010	6	view →
CCRCC	OS	Median	All	0.104	1.000	.044	3	view →
LSCC	DFS	Median	III,IV	0.850	0.489	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

REV3L–HNSC (DFS)

Open the HNSC breakdown →